Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment with nanosomal paclitaxel lipid suspension versus conventional paclitaxel in metastatic breast cancer patients - a multicenter, randomized, comparative, phase II/III clinical study.
Satheesh CT, Taran R, Singh JK, Shrivastav SP, Vithalani NK, Mukherjee KK, Nagarkar RV, Maksud T, Mehta AO, Srinivasan K, Vikranth M, Sonawane SR, Ahmad A, Sheikh S, Ali SM, Patel R, Paithankar M, Patel L, Rajani A, Bunger D, Chaturvedi A, Ahmad I. Satheesh CT, et al. Among authors: maksud t. Ther Adv Med Oncol. 2024 Apr 25;16:17588359241236442. doi: 10.1177/17588359241236442. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38680290 Free PMC article.
A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India.
Sinha SD, Biswas G, Bheemareddy BR, Chary S, Thakur P, Jain M, Maksud T, Pawar S, Chatterjee K, Voonna MK, Goel A, Puligundla KC, Lakshmaiah KC, Talluri L, Vattipalli R, Kakkunnath S. Sinha SD, et al. Among authors: maksud t. Cancer Inform. 2023 Jun 1;22:11769351231177277. doi: 10.1177/11769351231177277. eCollection 2023. Cancer Inform. 2023. PMID: 37313371 Free PMC article.
Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.
Chiradoni Thungappa S, Maksud T, Raut N, Nagarkar R, Batra U, Kumar S, Parmar D; Study Investigator Group. Chiradoni Thungappa S, et al. Among authors: maksud t. Clin Breast Cancer. 2022 Jun;22(4):300-307. doi: 10.1016/j.clbc.2021.11.006. Epub 2021 Nov 27. Clin Breast Cancer. 2022. PMID: 34955432 Clinical Trial.
Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study.
Gupta S, Biswas G, Babu S, Maksud TM, Lakshmaiah KC, Patel JG, Raja G, Boya RR, Patil P, Choudhury K, Bondarde SA, Neve RS, Bhat G, Mamillapalli G, Patel AA, Patel P, Joshi N, Bajaj V, Khan MA. Gupta S, et al. Among authors: maksud tm. Breast. 2021 Dec;60:147-154. doi: 10.1016/j.breast.2021.09.012. Epub 2021 Oct 1. Breast. 2021. PMID: 34624757 Free PMC article. Clinical Trial.